Behandlung allg./ treatment » Nirmatrelvir (Paxlovid) Pfizer

Letzte Änderung: 13.01.2022 um 11:10 Uhr

Paxlovid könnte der grosse Durchbruch bei der einfachen Behandlung vor kurzem erkrankter Risikopatienten sein. Es scheint auch gegen Omicron wirksam zu bleiben.


PF-07321332/ritonavir


"PF-07321332 is an investigational SARS-CoV-2-3CL protease inhibitor antiviral therapy, specifically designed to be administered orally so that it can potentially be prescribed at the first sign of infection or at first awareness of an exposure, without requiring patients to be hospitalized. Protease inhibitors, like PF-07321332, are designed to block the activity of the main protease enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir is expected to help slow the metabolism, or breakdown, of PF-07321332 in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus.


In March 2021, Pfizer progressed PF-07321332 to a Phase 1 study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of the investigational compound. In July, it progressed to a Phase 2/3 trial, EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients), to evaluate efficacy and safety, in combination with ritonavir, in participants with a confirmed diagnosis of SARS-CoV-2 infection who are at high risk of progression to severe illness. In August, Pfizer initiated a Phase 2/3 trial, EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients), to evaluate efficacy and safety in participants with a confirmed diagnosis of SARS-CoV-2 infection who are at standard risk (i.e., do not have risk factors for severe illness).


PF-07321332 is the first orally administered coronavirus-specific investigational protease inhibitor to be evaluated in clinical studies.


There is no orally administered therapy currently approved for post-exposure or pre-emptive treatment of COVID-19."


https://www.pfizer.com/news/press-release/press-release-detail/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19

Weiterführende Links zum Artikel

Mehr zum Thema "Behandlung allg./ treatment"

Mundspülung, Nasenspray, Nasenspülung/ mouthwash, nasal spray, nasal rinses 19. November 2020 08:57 weitere eventuell wirksame Nahrungsergänzungsmittel, Vitamine/ other supplements 25. Oktober 2020 21:00 weitere eventuell wirksame Medikamente/ other possibly effective drugs 25. Oktober 2020 20:56 Xevudy (Sotrovimab) GSK/Vir 22. Mai 2021 19:51 Vitamin D 25. Oktober 2020 20:31 Vitamin C 17. Dezember 2020 09:30 Tocilizumab (Actemra) 8. Januar 2021 10:48 soluble ACE2 20. Dezember 2021 13:05 Ronapreve / REGEN-COV (Casirivimab/Imdevimab) Regeneron/ Roche 7. Januar 2021 06:08 Regkirona (Regdanvimab) Celltrion 3. März 2021 09:09 Remdesivir 25. Oktober 2020 21:04 Oseltamivir 15. Dezember 2020 10:55 Melatonin 23. Januar 2021 10:07 Lagevrio (Molnupiravir) 10. Dezember 2020 10:46 Kineret (Anakinra) 17. Dezember 2021 10:54 Nirmatrelvir (Paxlovid) Pfizer 29. September 2021 12:10 DXP-604 14. Dezember 2021 14:53 Tofacitinib 20. Juni 2021 19:31 DZIF-10c (Boehringer) 14. Dezember 2021 10:01 Interferon 16. Dezember 2020 08:56 Immunglobulin/ immunoglobulin 25. Oktober 2020 20:43 Fluvoxamin/ Fluvoxamine 29. Oktober 2021 13:45 Evusheld ((Tixagevimab (AZD8895) und Cilgavimab (AZD1061)) Astra Zeneca (AZD7442) 24. August 2021 17:11 Kortison/ cortisone 25. Oktober 2020 20:50 Colchicin 23. Januar 2021 10:09 Bamlanivimab/ Etesevimab (Eli Lilly) 7. Januar 2021 06:12 Brii-196/198 (Romlusevimab) 17. Dezember 2021 13:14 Baricitinib 23. November 2020 16:18 Budesonide 12. April 2021 20:16 Antikoagulation/ anticoagulation 25. Oktober 2020 20:47 Adagio ADG 20 (Adintrevimab) 4. Dezember 2021 10:12 Antikörper/ antibodies 25. Oktober 2020 20:33 allgemeines/ general 21. November 2020 10:17

Weitere Themen

« Zurück zur Übersicht